Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03254485 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT03254485 is a Phase 2 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 196 participants.
The verdict
NCT03254485, a Phase 2 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
The objective of the CAPACITY-HFpEF study is to evaluate the safety and efficacy of IW-1973 compared with placebo when administered daily for approximately 12 weeks to patients with HFpEF. The study will evaluate the effect of oral IW-1973 on peak exercise capacity in patients with HFpEF, with or without permanent or persistent atrial fibrillation.
Interventions
- DRUG Placebo Oral Tablet
- DRUG IW-1973
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2017-11-07 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03254485
The ClinicalTrials.gov registry entry for NCT03254485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03254485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03254485 about?
NCT03254485 is a clinical study titled "A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)". The objective of the CAPACITY-HFpEF study is to evaluate the safety and efficacy of IW-1973 compared with placebo when administered daily for approximately 12 weeks to patients with HFpEF. The study will evaluate the effect of oral IW-1973 on peak exercise capacity in patients with HFpEF, with or wi...
What is the current status of trial NCT03254485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2017-11-07. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT03254485?
The interventions under investigation include: Placebo Oral Tablet (DRUG), IW-1973 (DRUG).
Who is sponsoring clinical trial NCT03254485?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.